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Significance of Thromboxane A 2 and 
Prostaglandin 12 in Acute Necrotizing 
Pancreatitis in Rats 
BART VAN OOIJEN, MD, PhD, WIL J. KORT, PhD, COR J. TINGA, MD, and J.H. PAUL WILSON 
Plasma thromboxane concentrations were found to be significantly elevated in acute 
necrotizing pancreatitis n rats, whereas prostaglandin 12 levels were not. The significance 
of these alterations was investigated. Pancreatitis was induced by injecting 5% sodium 
taurocholate into the pancreatic duct. Iloprost (ZK 36374, a stable analog of 
prostaglandin I 2, 25 ng/kg body weight) decreased the mortality rate from 100% to 50%. 
When treatment with iloprost was combined with simultaneous administration of either 
Sibelium (flunarizine R 14 950, 0.2 mg/kg body weight) or dazmegrel (UK 38 485, 50 mg/kg 
body weight) an additional decrease in the mortality rate was recorded. Dazmegrel is a 
selective thromboxane A 2 synthetase inhibitor and flunar&ine (a calcium entry blocker) 
also inhibits the effects of elevated thromboxane A 2 levels. With flunarizine and iloprost 
the mortality rate was 40% (P < 0.05); with dazmegrel and iloprost it was 10% (P < 0.01). 
The results of the present study suggest hat thromboxane A 2 and prostaglandin 12 play a 
role in the course of acute necrotizing pancreatitis. 
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Prostaglandins play an important role in the patho- 
physiology of several diseases (1). They possess 
potent and diverse biological activities. Thrombox- 
ane A 2 (TXA2) is a vasoconstrictor and stimulates 
platelet aggregation (1). Prostaglandin 12(PGI2) is a 
vasodilator and the most potent naturally occurring 
inhibitor of platelet aggregation yet discovered (2). 
These differences in biological activities have led to 
the development of new concepts in vascular and 
cellular homeostasis (3). 
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Recently we demonstrated that the plasma levels 
of thromboxane B2, the stable end-product of 
TXA 2, were elevated in acute necrotizing pancre- 
atitis (4, 5). The TXB z levels tend to rise dramati- 
cally compared with those of PGE 2 and I 2 (4). 
Simple inhibition of TXA2 synthesis and effects, 
however, did not alter survival time significantly 
(4), but with simultaneous administration f PGE2 a 
significant amelioration was encountered (6). 
In the present study we investigated the effects of 
iloprost (ZK 36 374, a stable PGI 2 derivate) (7-9) on 
the survival time of rats with acute pancreatitis. 
Iloprost was administered with and without simul- 
taneous inhibition of TXA 2 synthesis. The synthesis 
of TXA 2 was inhibited by dazmegrel (10) and fluna- 
rizine. Flunarizine, a calcium entry blocker, de- 
creases TXA 2 formation (5) and also inhibits the 
effects of raised TXA 2 concentrations (! 1). 
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MATERIALS AND METHODS 
Inbred male Wag/Rij rats, weighing 200-250 g, were 
used. Acute necrotizing pancreatitis (ANP) was induced 
by the retrograde injection of 5% sodium taurocholate 
(0.1 ml/100 g body weight) into the pancreatic duct as 
previously described (5). 
Iloprost (ZK 36 374) vials containing 1 ml of injection 
fluid No. SH L 401 A, were a gift from Schering AG, 
Berlin, West Germany. Final dilutions in physiological 
saline (10 ng/ml) were prepared on the day of injection. 
Test animals were injected subcutaneously with iloprost 
at the time of induction of ANP (zero time) and 1, 2, 3, 6, 
and 9 hr after induction in a dose of 25 ng/kg body weight. 
Control animals received 0.9% NaC1 instead of iloprost. 
Dilutions of dazmegrel (UK No. 38485, lot No. R22; 
Pfizer Central Research Laboratories, Sandwich, En- 
gland) in 0.1 N NaOH (12.5 mg/ml) were prepared on the 
day of administration. Experimental nimals received a 
dose of 50 mg/kg body weight dazmegrel via a gastric tube 
1 hr prior to the induction of ANP and 12 hr later. 
Flunarizine was a gift of Janssens Pharmaceuticals, 
Goirle, The Netherlands. Dilutions in 0.9% NaC1 (0.1 
mg/ml) were prepared on the day of injection. Experimen- 
tal animals were given flunarizine intravenously at the 
time of the induction of ANP in a dose of 0.2 mg/kg body 
weight. 
The rats were randomly assigned to one of four groups. 
Acute pancreatitis was induced in all groups: group 1 
(eight rats), saline; group 2 (eight rats), iloprost; group 3 
(10 rats), iloprost + dazmegrel; group 4 (10 rats), iloprost 
+ flunarizine. Survival time was recorded and survivors 
were sacrificed after a 72-hr observation period. Ascites 
was measured at autopsy by weighing cotton rolls satu- 
rated with the ascitic fluid. Fat necrosis was scored. The 
following scoring system was used: 0, scattered; 1, mild; 
2, moderate; 3, severe. The pancreas was removed, fixed 
in 4% buffered formalin, and embedded in paraffin. Sec- 
tions were cut and stained with hematoxylin and eosin. 
The sections of the pancreas were assessed by a pathol- 
ogist who was unaware of the treatment group. The 
amount of acinar necrosis was scored (0, <10%; 1, 
10-25%, 2, 25-50%; 3, >50%), as well as the interlobular 
edema, the inflammatory response, and the severity of 
hemorrhages (0, scattered; 1, mild; 2, moderate; 3, se- 
vere). The amounts of ascitic fluid for the different groups 
were compared using the Mann-Whitney U test, the 
histological scores using the chi-square test for 2 x r 
tables, and the survival data using Fischer's test for 2 x 
2 tables. 
RESULTS 
The effect of different reatments on the mortality 
rate for rats with acute necrotizing pancreatitis is 
shown in Table 1. Saline-treated animals exhibited a
100% mortality at 36 hr whereas treatment with 
iloprost (25 ng/kg body weight) reduced mortality to 
50%. The best results were obtained after treatment 
of the animals with flunarizine and dazmegrel. As- 
cites was found in all animals that died. The largest 
TABLE 1. MORTALITY* 
Time period (hr) 
Group 0-36 36-72 0-72 
ANP 100 0 100 
ANP + iloprost 50 0 50 
ANP + iloprost + F 40"~: 0 40*$ 
ANP + iloprost + D 10tS 10 20t~ 
*The mortality rate is expressed as the percentage of the animals 
that died in the several time periods. ANP = acute necrotizing 
pancreatitis: D= dazmegrel; F = flunarizine. 
*P < 0.05 statistically significant from ANP group. 
tP  < 0.01 statistically significant from ANP group. 
SNot statistically significant from ANP + iloprost group (chi- 
square tests for 2 • 2 table). 
amounts of ascitic fluid were found in the first 36 hr. 
The amount decreased significantly after treatment 
with the drugs (Table 2). Hydrothorax developed in 
some of the animals. In several cases a distended 
stomach with a paralytic ileus of the proximal bowel 
was found. Fat necrosis was seen in all animals that 
died of the disease within 36 hr. The necrosis was 
less pronounced in the animals that were treated 
with the drugs. The amount of necrosis tended to 
increase with time. A significantly lower amount of 
necrosis was found in animals treated with iloprost 
in combination with either flunarizine or dazmegrel 
(Table 3). 
Light microscopy studies of the pancreas (Fig- 
ures 1 and 2) showed an inflammatory infiltrate with 
areas of acinar necrosis. The inflammatory infiltra- 
tion became the most severe at 72 hr. Interlobular 
edema developed in all animals. No significant 
differences in inflammatory response, edema, and 
hemorrhages were seen between the several groups 
(Table 3). 
Acinar necrosis apparently continued, since ani- 
mals that survived for 72 hr exhibited a larger 
amount of necrosis than those that died within 36 
hr. Compared to the saline group, the acinar necro- 
TABLE 2. AMOUNT OF ASCITIC FLUID* 
Amount 
Group (g, mean +- SD) 
ANP 6.4 --- i.5 (8) 
ANP + iloprost 3.3 -+ 1.0 (8)t 
ANP + iloprost + F 2.0 + 0.8 (10)t 
ANP + iloprost + D 1.3 -+ 0.8 (10)t 
*The values are given in grams of ascites fluid and expressed as 
means - sD. The numbers of animals are indicated in paren- 
thesis. ANP = acute necrotizing pancreatitis. D = dazmegrel; F 
= flunarizine. 
~P < 0.01 statistically significant from ANP group (Mann- 
Whitney U test). 
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TABLE 3. HISTOLOGICAL SCORES* 
Scores 
Inflammatory lnterlobular 
Group Fat necrosis response edema Hemorrhage 
ANP (8) 2.3 -+ 0.7 1.0 -+ 0.6 2.0 -+ 0.8 1.0 -+ 0.5 
ANP + ilo (7) 1.5 -+ 0.8 1.6 -+ 0.8 1.3 -+ 1.1 0.6 -+ 0.5 
ANP + ilo + F (10) 0.4 -+ 0.5t$ 1.8 -+ 0.7 1.0 -+ 1.0 0.5 -+ 0.5 
ANP + ilo + D (9) 0.7 -+ 0.5t 1.9 -+ 1.0 0.9 -+ 0.8 0.6 -+ 0.7 
*The histological scores are given as means -+ SD. The numbers of animals are indicated in parenthesis. Score 0 = scattered, 1 = mild, 
2 = moderate, 3 = severe. ANP = acute necrotizing pancreatitis, ilo - iloprost, F = flunarizine, D = dazmegrel. Unless indicated 
otherwise scores are not statiscally significant. 
tP  < 0.01 statistically significant from ANP group. 
:~P < 0.05 statistically significant from ANP + ilo group. 
sis was less pronounced in the groups treated with 
drugs. The lowest amount of necrosis was found in 
the dazmegrel/iloprost group (Table 4). 
DISCUSSION 
Thromboxane A2 and prostaglandin 12 are prod- 
ucts of arachidonic acid with different and, in many 
respects, opposite biological activities. The interac- 
tion between platelet and vessel wall is responsible 
for eicosanoid production (3). TXAz is produced in 
response to ischemia in particular (12). The main 
effect of TXA 2 on the circulation is constriction of 
blood vessels and stimulation of platelet aggrega- 
tion with formation of microthrombi. As such it 
plays an important role in the macro- and microcir- 
culation of various organs. PGI 2 is a strong va- 
sodilatory agent that dilates all vascular beds with 
cytoprotective properties in the splanchnic area (2). 
A precise balance between TXA 2 and PGI 2 seems to 
be important for vascular and cellular homeostasis 
(3). 
Pancreatic blood flow decreases profoundly dur- 
ing the first hours of acute necrotizing pancreatitis 
(13, 14). Edema, poor vascular filling, and spastic 
changes in the lobular vessels have been observed 
(14). Eicosanoids may, in part, be responsible for 
these changes. 
TXA2 is generated (fourfold increase) in rats with 
acute pancreatitis (4, 5, 15), although not in dogs 
(16). In these rats thromboxane l vels are reduced 
by treatment with inhibitors of thromboxane syn- 
thesis of flunarizine (5). This inhibition tends to 
improve survival time in ANP (5). Plasma 6-keto- 
PGFI~ (the bioconversion product of PGI2) levels 
are increased to a much lesser extent (60% increase) 
(4, 15). PGI2 is an inhibitor of TXA2 production (2). 
The small increase in 6-keto PGFI~ levels may be 
the reflection of an insufficient response to the 
pathological stimuli. 
From the present series of experiments it is clear 
that TXA 2 and PGI  2 play a role in acute pancreatitis 
in rats. Administration of iloprost significantly im- 
proves the survival rate when TXA 2 is inhibited. 
Iloprost is easily absorbed into the general circula- 
tion and its pharmacological profile is well known 
(7-9). The interaction between prostanoids is in 
accordance with the opinion that one prostanoid 
may be the pharmacological inhibitor of the other 
and that their balance may be of more importance 
than the individual plasma levels (3, 6, 17). Other 
prostanoid mediators may play a more or less 
significant role as well (6). When prostaglandin 
synthesis is completely blocked by indomethacin (1
mg/kg), the course of ANP is not ameliorated at all 
(5), although no agreement exists (18-20). 
The mode of action of prostaglandin I 2 and throm- 
boxane A 2 in ANP is not clear. Their balance may 
protect he pancreas from ischemic damage. PGI  2 
may reduce the formation of activated pancreatic 
enzymes and their release into the systemic ircu- 
lation, because PGI 2 is known to reduce the forma- 
tion and release of lysosomal hydrolases, also in 
infarcted areas (2). Lysosomal hydrolases are 
thought o play a role in the intracellular activation 
process of proteolytic enzymes (21, 22). PGI2 ex- 
hibits a cytoprotective ffect on the pancreatic 
lysosomes in less advanced acute pancreatitis in 
dogs (23). This cytoprotective ffect may be a 
consequence of local vascular effects of PGI2, be- 
cause lysosomes are sensitive to stimuli such as 
ischemia, hypoxia, and acidosis (24). Histological 
examination of the pancreas howed that there was 
still considerable necrosis in treated animals, al- 
though there was a trend towards less severe histo- 
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Fig 1. Large areas of coagulative necrosis 12 hr after induction of ANP. The inflammatory response is almost 
absent. 
logical scores (Table 3 and 4). Relatively, the small- 
est percentage necrosis was seen in dazmegrel/ 
iloprost-pretreated animals (Table 4), which may 
point to cytoprotection as well. 
Local lesions of the pancreas are not exclusive 
factors of survival, because animals that were sac- 
rificed at 72 hr exhibited more necrosis and inflam- 
matory reaction than animals that died within 24 hr. 
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Fig 2A. Small areas of coagulative necrosis 24 hr after induction of ANP and treatment with iloprost. The 
inflammatory response is mild. Edema is present. 
It is possible that the balance between TXA2 and 
PGI2 is important for maintenance of a sufficient 
blood flow to vital organs until the large fluid loss 
into the peritoneal cavity stops. A lower amount of 
Fig 2B. The pancreas 72 hr after induction of ANP and administration of iloprost and Flunarizine. Areas of necrosis 
with a clear inflammatory response. 
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Fig 2C. The pancreas 72 hr after induction of ANP and treatment with iloprost and dazmegrel. Areas of acinar 
necrosis, normal architecture of peripancreatic fat tissue, mild inflammatory esponse. 
ascitic fluid had accumulated in pretreated animals. 
Absorption of toxic ascitic fluid into the general 
circulation is important for multiple organ failure. A 
protective effect of PGI2 on hepatic, renal and 
pulmonary lysosomes is reported to occur during 
acute pancreatitis n dogs (25-27). These organs are 
frequently damaged in the course of ANP. 
In summary, the results of this study indicate that 
thromboxane A 2 and prostaglandin 12 play a role in 
acute necrotizing pancreatitis. The present findings 
have yet to be tested in a clinical setting. It is 
promising that the bile-induced model in rats resem- 
TABLE 4. AMOUNT OF ACINAR NECROSIS* 
Scores 
Group Nonsurvivors Survivors All animals 
ANP 3.6 +_ 0.5 (8) (0) 3.6 _+ 0.5 (8) 
ANP + ilo 2.7 • 1.1 (3) 3.5 • 1.0 (4) 3.1 -+ 1.1 (7) 
ANP+ ilo + F 2.8-+ 1.0(4) 3.3 -+ 1.0(6) 3.1 -+ 1.0(10) 
ANP + ilo + D 2.5 --_0.7 (2)? 3.1 • 0.9 (7) 2.9 _+ 0.9 (9)t 
*The histological score of acinar necrosis is given as means • 
SD. The numbers of animals are indicated in parentheses. Score 
0 = <10% of the pancreas, 1 = 10-25%, 2 = 25-50%, 3 = 
>50%. ANP = acute necrotizing pancreatitis, ilo = iloprost, F 
= flunarizine, D = dazmegrel. 
:~P < 0.01 not statistically significant from ANP group (chi- 
square test for 2 x r tables). 
Digestive Diseases and Sciences. Vol. 35, No. 9 (September 1990) 
bles acute pancreatitis in man (28); the behavior of 
eicosanoids i also comparable (29). 
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